Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Virginia: - Kaiser Permanente-Burke Medical Center — Burke, Virginia
- University of Virginia Cancer Center — Charlottesville, Virginia
- Cancer Specialists of Tidewater Limited — Chesapeake, Virginia
- Peninsula Cancer Institute-Gloucester — Gloucester, Virginia
- Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
Phase 2, Phase 3 Recruiting Network
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
- Kaiser Permanente Tysons Corner Medical Center — McLean, Virginia
- Virginia Cancer Institute — Richmond, Virginia
- VCU Massey Cancer Center at Stony Point — Richmond, Virginia
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Virginia: - Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia
- Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
- Virginia Cancer Institute — Richmond, Virginia
- VCU Community Memorial Health Center — South Hill, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Virginia: - Local Institution - 007-814-A — Alexandria, Virginia
- Local Institution - 007-814-D — Arlington, Virginia
- USOR - Virginia Cancer Specialists - Fairfax Office — Fairfax, Virginia
- Local Institution - 007-814-B — Gainesville, Virginia
- Local Institution - 007-814-C — Leesburg, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Virginia: - Oncology & Hematology, Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer care — Low Moor, Virginia
- Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care — Salem, Virginia
- Shenandoah Oncology, P.C. — Winchester, Virginia
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Virginia: - Clinical Study Site — Blacksburg, Virginia
- Clinical Study Site — Charlottesville, Virginia
- Clinical Study Site — Fairfax, Virginia
- Clinical Study Site — Richmond, Virginia
- Clinical Study Site — Richmond, Virginia
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
- VCU Health Adult Outpatient Pavillion — Richmond, Virginia
Phase 3 Recruiting Industry
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…
Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Sites in Virginia: - NEXT Oncology - Virginia - 1129 — Fairfax, Virginia
- Virginia Cancer Institute - 1149 — Henrico, Virginia
- Virginia Oncology Associates - 1136 — Norfolk, Virginia
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has …
Sponsor: Pfizer
NCT ID: NCT07226999
Sites in Virginia: - Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Blacksburg, Virginia
- Virginia Oncology Associates — Chesapeake, Virginia
- Virginia Oncology Associates — Hampton, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Low Moor, Virginia
- Virginia Oncology Associates — Newport News, Virginia
Phase 3 Recruiting Industry
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with lo…
Sponsor: AstraZeneca
NCT ID: NCT05211895
Sites in Virginia: - Research Site — Arlington, Virginia
- Research Site — Fort Belvoir, Virginia
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
- Inova Fairfax Medical Campus — Falls Church, Virginia
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Virginia: - Virginia Cancer Specialists - Arlington — Arlington, Virginia
- Virginia Cancer Specialists — Fairfax, Virginia
- VCU Massey Cancer Center — Richmond, Virginia
- Shenandoah Oncology — Winchester, Virginia
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
- Virginia Commonwealth University (Vcu) — Richmond, Virginia
Phase 3 Recruiting Industry
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Virginia: - Virginia Cancer Specialists, PC — Fairfax, Virginia
Phase 3 Recruiting Industry
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
- Virginia Commonwealth University — Richmond, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in Virginia: - Johnston Willis Hospital — Richmond, Virginia
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Kaiser Permanente Tysons Corner Medical Center — McLean, Virginia
- Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 2 Recruiting Industry
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
Sponsor: Genentech, Inc.
NCT ID: NCT04302025
Sites in Virginia: - Virginia Cancer Specialists (Fairfax) - USOR — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Virginia: - USOR Virginia Cancer Specialists — Fairfax, Virginia
- USOR Virginia Oncology Associates — Norfolk, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 2 Recruiting Industry
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…
Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Virginia: - UVA Center for Psychiatric Clinical Research — Charlottesville, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Virginia: - Research Site 102 — Fairfax, Virginia
- Research Site 112 — Fairfax, Virginia